Visualized analysis in related literatures of lupus nephritis based on CiteSpace software
-
摘要:目的 基于CiteSpace软件对狼疮性肾炎相关文献进行可视化图谱分析。方法 以“lupus nephritis”为主题，检索Web of Science核心数据库相关文献，检索时间设置为2011年1月1日—2020年12月31日，应用CiteSpace软件对相关主题如作者、机构、国家、期刊等进行分析。结果 共收集5 397篇文献，发文量呈逐年上升的趋势；发文期刊多为风湿、免疫及药理类专刊，发文量前10的期刊平均影响因子为3分；CHAIM PUTTERMAN及CHANDRA MOHAN是狼疮性肾炎发文量最多的作者，分别发表41篇；WEENING J J成为最有影响力的作者，共被引1 007次；文献多来自美国和中国，发文量分别为1 005、985篇；文献被引次数前6位分别为241、193、166、156、136、129次，研究方向集中在诊断与治疗、专家共识及药物临床效果比较；关键词词频突现前5位分别为长期治疗、静滴环磷酰胺、硫唑嘌呤、补体及维持治疗。预测该领域的前沿热点是关于基础病理研究及药物临床效果的研究。结论 狼疮性肾炎领域总体研究已趋于完善。中国与外国的研究合作关系欠紧密，应进一步深入研究狼疮性肾炎的分子机制，并不断开展临床实验和动物实验，从而逐步完善该领域的研究体系。Abstract:Objective To perform a visualized analysis in related literatures of lupus nephritis (LN) based on CiteSpace software.Methods Based on the theme of "lupus nephritis", the related literatures in core database of Web of Science were searched from January 1, 2011 to December 31, 2020. CiteSpace software was used to analyze the related topics such as authors, institutions, countries and journals.Results A total of 5 397 literatures were collected, and the number of published papers showed an increasing trend year by year. The most papers were published in journals involving rheumatology, immunology and pharmacology, and the average impact factor of the top 10 published journals was 3 points. CHAIM PUTTERMAN and CHANDRA MOHAN were the author with the most published articles on LN (41 articles), and WEENING J J was the most influential author with 1 007 cited documents. The most of the literatures were from the United States and China, with 1 005 and 915 papers respectively. The numbers of the top 6 cited references were 241, 193, 166, 156, 136 and 129 times respectively, and the research topics focused on diagnosis and treatment, expert consensus and effect comparison between clinical drugs. The top 5 frequencies of keywords were long-term treatment, intravenous infusion of cyclophosphamide, azathioprine, complement and maintenance therapy. Prediction of the frontier hot spots in this field was about the basic pathological research and the clinical effect of drugs.Conclusion Overall research in the field of lupus nephritis has been improved. The research cooperation between China and foreign countries is not close, so we should further study its molecular mechanism, and continue to carry out clinical and animal experiments, so as to gradually improve the research system in this field.
-
-
表 1 2011—2020年LN相关发文期刊及影响因子
期刊名称 发文量/篇 影响因子(2019年) LUPUS 542 2.924 CLINICAL RHEUMATOLOGY 115 2.394 PLOS ONE 110 2.740 ARTHRITIS RESEARCH THERAPY 101 4.148 NEPHROLOGY DIALYSIS TRANSPLANTATION 94 4.531 RHEUMATOLOGY INTERNATIONAL 84 1.984 RHEUMATOLOGY 81 5.606 INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES 80 1.980 JOURNAL OF IMMUNOLOGY 78 4.886 FRONTIERS IN IMMUNOLOGY 76 5.085 
下载: 导出CSV
表 2 2011—2020年LN有关国家发文量及中介中心性
国家 频次/次 中介中心性 美国 1 005 0.39 英国 219 0.29 法国 113 0.17 比利时 159 0.14 加拿大 114 0.13
下载: 导出CSV
表 3 2011—2020年LN有关各学科发文量及中介中心性
学科 频次/次 中介中心性 风湿病学 1 412 0 泌尿外科及肾脏学 692 0.12 免疫学 629 0.19 普通内科 390 0.03 医学研究和实验 267 0.24 药理学 155 0.31 生物化学与分子生物学 140 0.17 科学与技术 135 0.01 综合科学 132 0.04 细胞生物学 127 0.26 儿科学 105 0.17 移植学 104 0.04 病理学 93 0.14 生命科学与生物医学 18 0.13 生物学 18 0.13 医用化学 13 0.10
下载: 导出CSV
表 4 2011—2020年LN有关的被引文献分析
被引文献 作者 被引频次/次 American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis HAHN B H等 241 Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis BERTSIAS G K等 193 Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study ROVIN B H等 166 Update on lupus nephritis ALMAANI S等 156 Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis APPEL G B等 136 Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis DOOLEY M A等 129
下载: 导出CSV
表 5 2011—2020年LN有关的共被引作者分析
共被引作者 频次/次 共被引作者 频次/次 WEENING J J 1 007 HAHN B H 554 HOCHBERG M C 935 MORONI G 529 PETRI M 695 GLADMAN D D 512 MOK C C 684 HOUSSIAU F A 495 AUSTIN H A 595 TAN E M 490
下载: 导出CSV
-
[1] SHANG X Y, REN L S, SUN G R, et al. Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity[J]. Immun Inflamm Dis, 2021, 9(2): 407-418. doi: 10.1002/iid3.401
[2] AYOUB I, NELSON J, ROVIN B H. Induction therapy for lupus nephritis: the highlights[J]. Curr Rheumatol Rep, 2018, 20(10): 60. doi: 10.1007/s11926-018-0766-9
[3] VON SCHEVEN E, BAKKALOGLU A. What's new in paediatric SLE[J]. Best Pract Res Clin Rheumatol, 2009, 23(5): 699-708. doi: 10.1016/j.berh.2009.07.008
[4] DER E, SURYAWANSHI H, MOROZOV P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type Ⅰ IFN and fibrosis relevant pathways[J]. Nat Immunol, 2019, 20(7): 915-927. doi: 10.1038/s41590-019-0386-1
[5] ARAZI A, RAO D A, BERTHIER C C, et al. The immune cell landscape in kidneys of patients with lupus nephritis[J]. Nat Immunol, 2019, 20(7): 902-914. doi: 10.1038/s41590-019-0398-x
[6] BRAGAZZI N L, WATAD A, DAMIANI G, et al. Role of anti-DNA auto-antibodies as biomarkers of response to treatment in systemic lupus erythematosus patients: hypes and hopes. Insights and implications from a comprehensive review of the literature[J]. Expert Rev Mol Diagn, 2019, 19(11): 969-978. doi: 10.1080/14737159.2019.1665511
[7] CHEN C M. CiteSpace Ⅱ: Detecting and visualizing emerging trends and transient patterns in scientific literature[J]. J Am Soc Inf Sci, 2006, 57(3): 359-377. doi: 10.1002/asi.20317
[8] CHEN C M. Searching for intellectual turning points: progressive knowledge domain visualization[J]. Proc Natl Acad Sci USA, 2004, 101(Suppl 1): 5303-5310. http://www.ncbi.nlm.nih.gov/pubmed/14724295/
[9] CHEN C M. Science mapping: a systematic review of the literature[J]. J Data Inf Sci, 2017, 2(2): 1-40. http://www.researchgate.net/publication/320831777_Science_Mapping_A_Systematic_Review_of_the_Literature
[10] NIAZI M, HUSSAIN A. Agent-based computing from multi-agent systems to agent-based models: a visual survey[J]. Scientometrics, 2011, 89(2): 479-499. doi: 10.1007/s11192-011-0468-9
[11] HAHN B H, MCMAHON M A, WILKINSON A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis[J]. Arthritis Care Res (Hoboken), 2012, 64(6): 797-808. doi: 10.1002/acr.21664
[12] BERTSIAS G K, TEKTONIDOU M, AMOURA Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis[J]. Ann Rheum Dis, 2012, 71(11): 1771-1782. doi: 10.1136/annrheumdis-2012-201940
[13] ROVIN B H, FURIE R, LATINIS K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study[J]. Arthritis Rheum, 2012, 64(4): 1215-1226. doi: 10.1002/art.34359
[14] ALMAANI S, MEARA A, ROVIN B H. Update on lupus nephritis[J]. Clin J Am Soc Nephrol, 2017, 12(5): 825-835. doi: 10.2215/CJN.05780616
[15] APPEL G B, CONTRERAS G, DOOLEY M A, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis[J]. J Am Soc Nephrol, 2009, 20(5): 1103-1112. doi: 10.1681/ASN.2008101028
[16] DOOLEY M A, JAYNE D, GINZLER E M, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis[J]. N Engl J Med, 2011, 365(20): 1886-1895. doi: 10.1056/NEJMoa1014460
[17] COSTAGLIOLA G, MOSCA M, MIGLIORINI P, et al. Pediatric systemic lupus erythematosus: learning from longer follow up to adulthood[J]. Front Pediatr, 2018, 6: 144. doi: 10.3389/fped.2018.00144
[18] GROOT N, DE GRAEFF N, MARKS S D, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative[J]. Ann Rheum Dis, 2017, 76(12): 1965-1973. doi: 10.1136/annrheumdis-2017-211898
[19] MINA, VON SCHEVEN E, ARDOIN S P, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2012, 64(3): 375-383. doi: 10.1002/acr.21558
[20] GREENBERG J H, KAKAJIWALA A, PARIKH C R, et al. Emerging biomarkers of chronic kidney disease in children[J]. Pediatr Nephrol, 2018, 33(6): 925-933. doi: 10.1007/s00467-017-3701-9
[21] TUNNICLIFFE D J, PALMER S C, HENDERSON L, et al. Immunosuppressive treatment for proliferative lupus nephritis[J]. Cochrane Database Syst Rev, 2018, 6: CD002922.
[22] BROEN J C A, VAN LAAR J M. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology[J]. Nat Rev Rheumatol, 2020, 16(3): 167-178. doi: 10.1038/s41584-020-0374-8
[23] AGGARWAL A, PHATAK S, SRIVASTAVA P, et al. Outcomes in juvenile onset lupus: single center cohort from a developing country[J]. Lupus, 2018, 27(11): 1867-1875. doi: 10.1177/0961203318791046
[24] ARGOLINI L M, FRONTINI G, ELEFANTE E, et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up[J]. J Nephrol, 2021, 34(2): 389-398. doi: 10.1007/s40620-020-00753-w
[25] SMITH E M D, LEWANDOWSKI L B, JORGENSEN A L, et al. Growing international evidence for urinary biomarker panels identifying lupus nephritis in children-verification within the South African Paediatric Lupus Cohort[J]. Lupus, 2018, 27(14): 2190-2199. doi: 10.1177/0961203318808376
[26] SMITH E M D, YIN P, JORGENSEN A L, et al. Clinical predictors of active LN development in children-evidence from the UK JSLE Cohort Study[J]. Lupus, 2018, 27(13): 2020-2028. doi: 10.1177/0961203318801526
[27] MA X X, NAKAYAMADA S, KUBO S, et al. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors[J]. Ann Rheum Dis, 2018, 77(9): 1354-1361. doi: 10.1136/annrheumdis-2017-212652
[28] BRIGHTBILL H D, SUTO E, BLAQUIERE N, et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus[J]. Nat Commun, 2018, 9(1): 179. doi: 10.1038/s41467-017-02672-0
[29] CORREA-RODRÍGUEZ M, POCOVI-GERARDINO G, CALLEJAS-RUBIO J L, et al. Vitamin D levels are associated with disease activity and damage accrual in systemic lupus erythematosus patients[J]. Biol Res Nurs, 2021, 23(3): 455-463. http://www.researchgate.net/publication/348108637_Vitamin_D_Levels_are_Associated_with_Disease_Activity_and_Damage_Accrual_in_Systemic_Lupus_Erythematosus_Patients
[30] PETRI M, BELLO K J, FANG H, et al. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio[J]. Arthritis Rheum, 2013, 65(7): 1865-1871. http://lupus.bmj.com/lookup/external-ref?access_num=23553077&link_type=MED&atom=%2Flupusscimed%2F1%2F1%2Fe000027.atom
[31] WU X Q, ZHANG H, ZHANG S, et al. Vitamin D receptor is negatively correlated with interferon-γ-inducible protein-10 in systemic lupus erythematosus with renal involvement[J]. Eur J Inflamm, 2020, 18: 205873922094233. http://www.researchgate.net/publication/343632250_Vitamin_D_receptor_is_negatively_correlated_with_interferon-g-inducible_protein-10_in_systemic_lupus_erythematosus_with_renal_involvement
[32] GODRON-DUBRASQUET A, WOILLARD J B, DECRAMER S, et al. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis[J]. Pediatr Nephrol, 2021, 36(2): 341-347. doi: 10.1007/s00467-020-04733-x
[33] PUTERA A M, IRWANTO I, MARAMIS M M, et al. Effect of mental health problems on the quality of life in children with lupus nephritis[J]. Neuropsychiatr Dis Treat, 2020, 16: 1583-1593. http://www.researchgate.net/publication/342474350_Effect_of_Mental_Health_Problems_on_the_Quality_of_Life_in_Children_with_Lupus_Nephritis
[34] GATTO M, RADU C M, LUISETTO R, et al. Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings[J]. J Autoimmun, 2020, 111: 102443. http://www.sciencedirect.com/science/article/pii/S0896841120300561
[35] FURIE R, ROVIN B H, HOUSSIAU F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128. http://www.researchgate.net/publication/344291642_Two-Year_Randomized_Controlled_Trial_of_Belimumab_in_Lupus_Nephritis
[36] ATISHA-FREGOSO Y, MALKIEL S, HARRIS K M, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis[J]. Arthritis Rheumatol, 2021, 73(1): 121-131. doi: 10.1002/art.41466
计量
- 文章访问数:
- HTML全文浏览量:
- PDF下载量:
苏公网安备 32100302010246号